Screening for lupus anticoagulants in patients treated with vitamin K antagonists

International Journal of Laboratory Hematology

Volumn 37, Issue 6, 2015, Pages 758-765

  Isert, M ^a   Miesbach, W ^a   Stoever, G ^a   Lindhoff Last, E ^a   Linnemann, B ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Medical Practice of Angiology and Haemostaseology   (Germany)

Author keywords

anticoagulation; antiphospholipid syndrome; dilute Russell's viper venom time; Lupus anticoagulants; vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHENPROCOUMON; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REFERENCE VALUE; RELIABILITY; RUSSELL VIPER VENOM TIME RATIO; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM;

EID: 84973441858     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12409     Document Type: Article

References (36)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295–306.
2. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–40.
3. Galli M. Phospholipid inhibitors. State of the art. Haemostaseologie 2011;31:243–50.
4. Pradella P, Azzarini G, Santarossa L, Caberlotto L, Bardin C, Poz A, D'Aurizio F, Giacomello R. Cooperation experience in a multicenter study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays. Clin Chem Lab Med 2013;51:379–85.
5. Favaloro EJ. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 2013;51:253–6.
6. Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011;49:447–61.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group. Antiphosopholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–27.
8. Chandler JB, Torres R, Rinder HM, Tormey CA. Lupus anticoagulant testing and anticoagulation do not mix: quantification of discrepant results and potential approaches to reduce false positives. Br J Haematol 2014;167:697–726.
9. Tripodi A. Testing for lupus anticoagulants: all that a clinician should know. Lupus 2009;18:291–8.
10. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; the British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47–58.
11. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:1125–32.
12. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012;38:339–47.
13. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress of Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685–96.
14. Lindhoff-Last E, Humpich M, Schmitt J, Roediger S, Seifried E, Bauersachs R. MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 2002;8:163–7.
15. Favaloro EJ. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Lab Hematol 2013;35:269–74.
16. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012;38:348–52.
17. Swadzba J, Iwaniec T, Pulka M, de Laat B, de Groot PG, Musial J. Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost 2011;9:1776–83.
18. Ledford-Kraemer M, Moore GW, Bottenus R, Daniele C, deGroot PG, Exner T, Favaloro EJ, Moffat KA, Nichols WL. Laboratory testing for the lupus anticoagulant. Approved guideline, 1st edn. CLSI document C60. Wayne, PA: Clinical and Laboratory Standards Institute; 2014;34:1–94.
19. Rooney AM, McNally T, Mackie IJ, Machin SJ. The Taipan snake venom time: a new test for lupus anticoagulant. J Clin Pathol 1994;47:497–501.
20. Speijer H, Govers-Riemslag JW, Zwaal RF, Rosing J. Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (Taipan snake). J Biol Chem 1986;261:13258–67.
21. Parmar K, Lefkou E, Goughty H, Connor P, Hunt BJ. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagul Fibrinolysis 2009;20:271–5.
22. Moore GW, Smith MP, Savidge F. The ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagul Fibrinolysis 2003;14:307–12.
23. van Os GM, de Laat B, Kamphuisen PW, Meijeers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011;9:1657–9.
24. Morelli VM, Rodigrues CA, Noguti MA, Matos MF, da Silveira RC, Martinez Ribeiro AA, Lourenco DM. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism. Blood Coagul Fibrinolysis 2007;18:401–5.
25. Chantarangkul V, Biguzzi E, Asti D, Palmucci C, Tripodi A. Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on lupus anticoagulant. Thromb Haemost 2013;110:46–52.
26. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell's viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869–74.
27. Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coagul Fibrinolysis 1990;1:627–32.
28. Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clin Lab 2009;55:138–42.
29. Pennings MT, de Groot PG, Meijers JC, Huisman A, Derksen HW, Urbanus RT. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? Thromb Haemost 2014;112:736–42.
30. Martinuzzo ME, Barrera LH, D'Adamo MA, Toaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014;36:144–50.
31. Devreese KMJ. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants? J Thromb Haemost 2010;8:1120–2.
32. Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems. Blood Coagul Fibrinolysis 2012;23:739–44.
33. Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010;8:2828–31.
34. Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol 2014;36:364–73.
35. Tripodi A, Pengo V. More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2011;9:2126–7.
36. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl. 1):S1–266.